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Abstract: Cancer remains one of the leading causes of mortality worldwide and the associated 
reduction in physical function has a marked impact on both quality of life and survival. The aim of 
the present study was to examine the relationship between Eastern Cooperative Oncology Group-
Performance status (ECOG-PS), modified Glasgow Prognostic Score (mGPS), Body Mass Index/ 
Weight Loss grade (BMI/WL grade), and Computerised Tomography (CT)-derived body 
composition measurement and physical function in patients with advanced cancer. Nine sites 
contributed prospective data on patient demographics, ECOG-PS, mGPS, physical function tests, 
and CT-derived body composition. Categorical variables were analysed using χ2 test for linear-by-
linear association, or χ2 test for 2-by-2 tables. Associations were analysed using binary logistic 
regression. A total of 523 cancer patients (266 males, 257 females) were included in the final analysis 
and most had metastatic disease (83.2%). The median overall survival was 5.6 months. On 
multivariate binary logistic regression analysis, a high ECOG-PS remained independently 
associated with a low skeletal muscle index (p < 0.001), low skeletal muscle density (p < 0.05), and 
timed up and go test failure (p < 0.001). A high mGPS remained independently associated with a 
low skeletal muscle density (p < 0.05) and hand grip strength test failure (p < 0.01). A high BMI/WL 
grade remained independently associated with a low subcutaneous fat index (p < 0.05), low visceral 
obesity (p < 0.01), and low skeletal muscle density (p < 0.05). In conclusion, a high ECOG-PS and a 
high mGPS as outlined in the ECOG-PS/mGPS framework were consistently associated with poorer 
body composition and physical function in patients with advanced cancer. 
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1. Introduction 
Cancer remains one of the leading causes of mortality worldwide and is responsible for 8.8 
million deaths each year. In westernised countries, it has been estimated that one in three people will 
develop cancer in their lifetime and one in four will die from it [1,2]. 
The importance of cachexia syndrome, with escalating nutritional and functional decline leading 
to poor clinical outcomes, is well recognised [3]. However, how this complex syndrome is best 
defined is the subject of continuing debate. Clearly, defining any syndrome is difficult due to its 
multifaceted nature. However, in such circumstances one may resort to the duck test approach: “If it 
looks like a duck, swims like a duck, quacks like a duck, then it probably is a duck”. Such abductive 
reasoning has been commonly used to settle legal cases and more recently has gained popularity in 
artificial intelligence. 
In the context of cancer cachexia, a number of factors have been shown to impact independently 
on quality of life (including functional and symptom scores) and survival. These include Eastern 
Cooperative Oncology Group-Performance status (ECOG-PS) and the systemic inflammatory 
response (modified Glasgow Prognostic Score, mGPS), both of which have been extensively validated 
[4–7]. More recently, based on an international consensus, body mass index/weight loss (BMI/WL) 
grades have been shown to impact independently on quality of life and survival [8–10]. 
Recently, these three criteria for the definition of cancer cachexia were directly compared and all 
three independently predicted survival in patients with advanced cancer [11]. However, BMI/WL 
grade was low risk in approximately 50% of patients and ECOG-PS and mGPS were independently 
associated with survival in this group. Therefore, to further investigate the clinical utility of these 
three criteria to define cachexia, the aim of the present study was to examine the relationship between 
ECOG-PS, mGPS, BMI/WL grade, and Computerised Tomography (CT)-derived body composition 
and physical function tests in patients with advanced cancer. 
2. Patients and Methods 
2.1. Patients 
A biobank of data from patients with advanced cancer was analysed. All data were collected 
prospectively across 9 sites in the UK and Ireland (cancer centres, hospitals, and specialist palliative 
care units) over a five-year period (2011–2016)[9,11,12]. Eligible patients provided written informed 
consent, were adults, had advanced cancer including all cancer subtypes (defined as metastatic cancer 
with histological, cytological or radiological evidence, that was locally advanced, or receiving anti-
cancer therapy with palliative intent) and had the ability to comply with study procedures including 
provision of a venous blood sample (taken on the day of consent). Patients were either inpatients or 
outpatients, undergoing anti-cancer therapy with a palliative intent including best supportive care. 
The study had ethical approval in both the UK and Ireland (UK-12/SS/0181 and Ireland EMC 4(g) 
2015) and was conducted in accordance with the Declaration of Helsinki. Furthermore, the study 
conformed to the STROBE guidelines for cohort studies [13]. 
2.1.1. Prognostic Markers 
Patient’s age, sex, and clinicopathological characteristics were recorded within 3 months prior 
to study entry. Prognostic tools/factors validated in a recent systematic review by Simmons and co-
workers were used in the analysis [14]. 
Patients were categorized according to their ECOG-PS into five district grades (grade 0–4) as 
previously described [15]. The mGPS was constructed as previously described (CRP ≤10 mg/L = 0, 
CRP >10 mg/L & albumin ≥35g/L = 1, CRP >10mg/L and albumin <35g/L = 2) [16,17]. An autoanalyzer 
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was used to measure serum CRP (mg/L) and albumin (g/L) concentrations (Architect; Abbot 
Diagnostics, Maidenhead, UK). Patients were categorized according to the BMI-adjusted weight loss 
grade into one of five distinct weight loss grades (grades 0–4) as previously described [8,9]. 
2.1.2. Body Composition 
CT images were obtained at the level of the third lumbar vertebra [18]. Patients whose scans 
were taken ≥ 3 months prior to study entry, who had significant movement artefact, or who were 
missing the region of interest were excluded. CT images were analysed using NIH Image J version 
1.47 (U. S. National Institutes of Health, Bethesda, USA) or OsiriX software version 4.1.1 (OsiriX, 
Geneva , Switzerland). Both imaging software packages have been shown to provide excellent 
agreement for body composition measures[19]. Region of interest (ROI) measurements were made of 
visceral fat areas, subcutaneous fat areas (Table 1), and skeletal muscle areas (cm2) (Table 1) using 
standard Hounsfield Unit (HU) ranges (adipose tissue -190 to -30, and skeletal muscle -29 to +150). 
These were then normalised for height2 to create indices: total fat index (cm2/m2), subcutaneous fat 
index (cm2/m2), visceral fat index (cm2/m2), and skeletal muscle index (cm2/m2). Skeletal muscle 
radiodensity (HU) was measured from the same ROI used to calculate skeletal muscle index, as its 
mean HU. 
Table 1. CT-derived body composition measures and thresholds used. 
Body Composition Measurement  
High subcutaneous fat index [20]: 
Subcutaneous fat area: Males >50.0 cm2m2 and Females >42.0 cm2m2  
Visceral obesity [21,22]: 
Visceral fat area: Males >160 cm2 and Females >80 cm2 
Sarcopenia  
Low skeletal muscle index [22]: 
Males: BMI <25kg/m2 and skeletal muscle index <43 cm2m2 or BMI >25kg/m2 
and skeletal muscle index <53 cm2m2 
Females: BMI <25kg/m2 and skeletal muscle index <41 cm2m2 or BMI 
>25kg/m2 and skeletal muscle index <41 cm2m2 
Myosteatosis 
Low skeletal muscle radiodensity [22]: 
BMI <25kg/m2 and skeletal muscle radiodensity <41 HU or BMI >25kg/m2 
and skeletal muscle radiodensity <33 HU 
Visceral obesity was defined by Doyle and colleagues as a visceral fat area >160cm2 for male 
patients and >80cm2 for female patients [23]. High subcutaneous fat was defined by Ebadi and 
colleagues as a subcutaneous fat index ≥ 50.0 cm2m2 in males and ≥42.0 cm2m2 in females [20]. Low 
skeletal muscle index was defined as described by Martin and colleagues, with a skeletal muscle 
index <43cm2/m2 if BMI <25kg/m2 and skeletal muscle index <53cm2/m2 if BMI ≥25kg/m2 in male 
patients and skeletal muscle index <41cm2/m2 in female patients [22]. Low skeletal muscle 
radiodensity was defined by Martin and colleagues as an skeletal muscle radiodensity <41HU in 
patients with BMI <25kg/m2 and <33HU in patients with BMI ≥25kg/m2 (Table 1) [22]. 
Two individuals performed scan measurements (Dolan and Daly). In order to assess accuracy, 
inter-rater reliability was measured in a test cohort of 20 patient images. Inter-class correlation 
coefficients were 0.986 for skeletal muscle area and 0.964 for skeletal muscle radiodensity. 
Investigators were blind to patient’s demographic and clinico-pathological status. 
2.1.3. Physical Function 
Eastern Cooperative Performance Status (ECOG-PS), timed up and go, two-minute walk, and  
hand grip strength tests, as well as the presence of metastases and weight loss over the preceding 
three months to study entry, were assessed by either the treating clinician or clinical research staff. 
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Timed up and go test and two-minute walk test completion were recorded contemporaneously with 
completion being recorded as a test pass. A failure of timed up and go has previously been defined 
by Kear and co-workers for patients under 60 and by Rockwood and co-workers in patients over 60 
[24–26]. A failure of the two-minute walk test has previously been defined by Bohannon and co-
workers for male and female patients between 18 and 85 years of age [27]. A weak hand grip strength 
test was defined by Studenski and co-workers as <26 kg in men and <16kg in women [28]. Patients 
who achieved a hand grip strength results below the above thresholds were deemed to have failed 
the hand grip strength test. 
2.2. Statistical Analysis 
Body composition measurements were presented as median and range and compared using 
Mann–Whitney or Kruskal–Wallis tests. Categorical variables were analysed using χ2 test for linear-
by-linear association, or χ2 test for 2-by-2 tables. 
Associations between ECOG-PS, mGPS, BMI-WL grades, body composition, physical function 
tests, and survival were analysed using univariate and a multivariate backward conditional 
approach. A p < 0.05 was applied to inclusion at each step in the multivariate analysis. 
Missing data were excluded from analysis on a variable by variable basis. Two-tailed p values 
<0.05 were considered statistically significant. Statistical analysis was performed using SPSS software 
version 21.0. (SPSS Inc., Chicago, IL, USA). 
3. Results 
A total of 523 patients (266 males, 257 females) satisfied the inclusion criteria. The relationship 
between clinicopathological characteristics, body composition, and physical function is shown in 
Table 2. The majority of patients were over 65 (56.8%), had a BMI >25kg/m2 (50.1%), and had 
metastasis (83.2%). Gastrointestinal (34.4%) and lung (31.7%) cancers were the most common 
tumours. The median overall survival was 5.6 months (95% CI: 5.1–6.0 months). At the date of 
censoring, 318 patients (61%) were dead. Median follow-up time for patients that had died was 10.5 
months (95% CI: 9.0–12.1 months). 
Table 2. Clinicopathological characteristics of patients who met the inclusion criteria (n = 523). 
Characteristic n = 523 (%) 
 Clinico-pathological  
Age <65 226 (43.2) 
 65–74 165 (31.5) 
 >74 132 (22.5) 
Sex Male 266 (50.9) 
 Female 257 (49.1) 
Cancer Location Lung 177 (33.8) 
 Gastrointestinal  180 (34.4) 
 Other 166 (31.7) 
Metastatic Disease No 88 (16.8) 
 Yes 435 (83.2) 
 Previous Anti-Cancer Therapy  
Chemotherapy No 149 (28.5) 
 Yes 374 (71.5) 
Radiotherapy No 362 (69.2) 
 Yes 161 (30.8) 
Hormones No 470 (89.9) 
 Yes 53 (10.1) 
 Performance status  
ECOG-PS   
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Low Risk 0/1 255 (48.8) 
Intermediate Risk 2 204 (39.0) 
High Risk 3/4 64 (12.2) 
Timed up and go test ˥ Pass 125 (30.9) 
 Fail 279 (69.1) 
Two-minute walk test ˦ Pass 10 (2.5) 
 Fail 393 (97.5) 
Hand grip strength test ˧ Pass  74 (62.2) 
 Fail 45 (37.8) 
 Systemic Inflammation  
mGPS   
Low Risk 0 217 (41.5) 
Intermediate Risk 1 91 (17.4) 
High Risk 2 215 (41.1) 
 Body composition  
BMI ≤20.0 kg/m2 74 (14.1) 
 20–21.9 kg/m2 70 (13.4) 
 22–24.9 kg/m2 117 (22.4) 
 25–27.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 155 (29.6) 
% Weight Loss <2.5 292 (56.0) 
 ≥2.5 231 (44.0) 
BMI/WL grade   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subcutaneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41.1) 
 High 113 (58.9) 
Low skeletal muscle index ˩ No 162 (53.3) 
 Yes 142 (46.7) 
Low skeletal muscle radiodensity ˪ No 116 (39.7) 
 Yes 176 (60.3) 
˥: 404, ˦: 403, ˧: 119, ˨: 192, ˩:304, ˪: 292. 
The relationship between ECOG-PS and measures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
Table 3a      
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
Table 3b      
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
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All 91 77 24 192  
Table 3c      
Low skeletal muscle index n = 304 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 101 (59.8) 49 (45.8) 12 (42.9) 162 (53.3) 0.039 
Yes 68 (40.2) 58 (54.2) 16 (57.1) 142 (46.7)  
All 169  107  28 304  
Table 3d      
Low skeletal muscle radiodensity n = 292 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 74 (46.5) 40 (38.5) 2 (7.4) 116 (39.7) 0.001 
Yes 85 (53.5) 66 (61.5) 25 (92.6) 176 (60.3)  
All 159 104 27 292  
Table 3e      
Timed up and go test failure n = 404 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 94 (54.3) ¥ 29 (17.0) 2 (3.3) 125 (30.9) <0.001 
Yes 79 (45.7) 142 (83.0) 58 (96.7) 279 (69.1)  
All 173 171 60 404  
Table 3f      
Hand grip strength test failure n = 119 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 56 (68.3) 16 (48.5) 2 (50.0) 74 (62.2) 0.123 
Yes 26 (31.7) 17 (51.5) 2 (50.0) 45 (37.8)  
All 82 33 4 119  
The relationship between mGPS and measures of body composition and physical function are 
shown in Table 4. mGPS was significantly associated with skeletal muscle radiodensity (p < 0.01), 
timed up and go test failure (p ≤ 0.001), and hand grip strength test failure (p < 0.01). 
Table 4. The relationship between modified Glasgow Prognostic Score (mGPS), and measures of body 
composition and physical function in patients with advanced cancer (n = 523). 
Table 4a      
High subcutaneous fat index n = 192 mGPS = 0 mGPS = 1 mGPS = 2 All p 
No 22 (29.3) 5 (16.7) 27 (31.0) 54 (28.1) 0.306 
Yes 53 (70.7) 25 (83.3) 60 (69.0) 138 (71.9)  
All 75 30 87 192  
Table 4b      
High visceral obesity n = 192 mGPS = 0 mGPS = 1 mGPS = 2 All p 
No 32 (42.7) 9 (30.0) 38 (43.7) 79 (41.1) 0.398 
Yes 43 (57.3) 21 (70.0) 49 (56.3) 113 (58.9)  
All 75 30 87 192  
Table 4c      
Low skeletal muscle index n = 304 mGPS = 0 mGPS = 1 mGPS = 2 All p 
No 72 (55.4) 27 (61.4) 63 (48.5) 162 (53.3) 0.273 
Yes 58 (44.6) 17 (38.6) 67 (51.5) 142 (46.7)  
All 130 44 130 304  
Table 4d      
Low skeletal muscle radiodensity n = 292 mGPS = 0 mGPS = 1 mGPS = 2 All p 
No 62 (50.4) 15 (34.1) 39 (31.2) 116 (39.7) 0.006 
Yes 61 (49.6) 29 (65.9) 86 (68.8) 176 (60.3)  
All 123 44 125 292  
Table 4e      
Timed up and go test failure n = 404 mGPS = 0 mGPS = 1 mGPS = 2 All p 
No 66 (41.3) 21 (27.6) 38 (22.6) 125 (30.9) 0.001 
Yes 94 (58.8) 55 (72.4) 130 (77.4) 279 (69.1)  
All 160 76 168 404  
Table 4f      
Hand grip strength test failure n = 119 mGPS = 0 mGPS =1 mGPS = 2 All p 
No 44 (77.2) 8 (53.3) 22 (46.8) 74 (62.2) 0.005 
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Yes 13 (22.8) 7 (46.7) 25 (53.2) 45 (37.8)  
All 57 15 47 119  
The relationship between BMI/WL grade and measures of body composition and physical 
function are shown in Table 5. BMI/WL grade was significantly associated with visceral obesity (p < 
0.05) and skeletal muscle radiodensity (p < 0.01). 
Table 5. The relationship between body mass index/weight loss (BMI/WL) grade and measures of 
body composition and physical function measurements in patients with advanced cancer (n = 523). 
Table 5a      
High subcutaneous fat index n = 
192 
BMI/WL grade 
0/1 
BMI/WL grade 
2/3 
BMI/WL grade 
4 
All p 
No 20 (22.0) 23 (30.7) 11 (42.3) 54 (28.1) 0.104 
Yes 71 (78.0) 52 (69.3) 15 (57.7) 
138 
(71.9) 
 
All 91 75 26 192  
Table 5b      
High visceral obesity n = 192 
BMI/WL grade 
0/1 
BMI/WL grade 
2/3 
BMI/WL grade 
4 
All p 
No 30 (33.0) 33 (44.0) 16 (61.5) 79 (41.1) 0.027 
Yes 61 (67.0) 42 (56.0) 10 (38.5) 
113 
(58.9) 
 
All 91 75 26 192  
Table 5c      
Low skeletal muscle index n = 304 
BMI/WL grade 
0/1 
BMI/WL grade 
2/3 
BMI/WL grade 
4 
All p 
No 93 (57.8) 56 (51.9) 13 (37.1) 
162 
(53.3) 
0.080 
Yes 68 (42.2) 52 (48.1) 22 (62.9) 
142 
(46.7) 
 
All 161 108 35 304  
Table 5d      
Low skeletal muscle radiodensity n 
= 292 
BMI/WL grade 
0/1 
BMI/WL grade 
2/3 
BMI/WL grade 
4 
All p 
No 70 (45.8) 41 (39.4) 5 (14.3) 
116 
(39.7) 
0.003 
Yes 83 (54.2) 63 (60.6) 30 (85.7) 
176 
(60.3) 
 
All 153 104 35 292  
Table 5e      
Timed up and go test failure n = 404 
BMI/WL grade 
0/1 
BMI/WL grade 
2/3 
BMI/WL grade 
4 
All p 
No 68 (33.7) 41 (28.9) 16 (26.7) 
125 
(30.9) 
0.473 
Yes 134 (66.3) 101 (71.1) 44 (73.3) 
279 
(69.1) 
 
All 202 142  60 404  
Table 5f      
Hand grip strength test failure n = 
119 
BMI/WL grade 
0/1 
BMI/WL grade 
2/3 
BMI/WL grade 
4 
All p 
No 47 (63.5) 21 (58.3) 6 (66.7) 74 (62.2) 0.835 
Yes 27 (36.5) 15 (41.7) 3 (33.3) 45 (37.8)  
All 74 36 9 119  
Low skeletal muscle radiodensity was significantly associated with timed up and go test failure 
(n = 192, p = 0.015) and hand grip strength failure (n = 100, p = 0.042). 
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The relationship between ECOG-PS, mGPS, BMI/WL grade, and subcutaneous fat index in 
patients with advanced cancer is shown in Table 6a. On multivariate binary logistic regression 
analysis, BMI/WL grade (OR 0.62, 95%CI 0.40–0.97, p < 0.05) remained independently associated with 
a high subcutaneous fat index. 
Table 6. The relationship between ECOG-PS, mGPS, BMI/WL grade and skeletal muscle index, 
skeletal muscle radiodensity and physical function in patients with advanced cancer (n = 523). 
Table 6a      
High subcutaneous fat index Univariate p-value Multivariate p-value 
ECOG-PS 1.13 (0.71–1.78) 0.617 ─ 0.319 
mGPS 0.95 (0.67–1.34) 0.776 ─ 0.995 
BMI/WL Grade 0.62 (0.40–0.97) 0.036 0.62 (0.40–0.97) 0.036 
Table 6b     
High visceral obesity Univariate p-value Multivariate p-value 
ECOG-PS 1.12 (0.74–1.70) 0.606 ─ 0.254 
mGPS 0.97 (0.71–1.33) 0.865 ─ 0.844 
BMI/WL Grade 0.57 (0.38–0.87) 0.009 0.57 (0.38–0.87) 0.009 
Table 6c     
Low skeletal muscle index Univariate p-value Multivariate p-value 
ECOG-PS 1.53 (1.08–2.17) 0.016 1.90 (1.51–2.39) <0.001 
mGPS 1.15 (0.90–1.47) 0.264 ─ 0.768 
BMI/WL Grade 1.44 (1.03–2.00) 0.033 ─ 0.106 
Table 6d     
Low skeletal muscle radiodensity Univariate p-value Multivariate p-value 
ECOG-PS 2.01 (1.36–2.98) <0.001 1.68 (1.11–2.55) 0.013 
mGPS 1.50 (1.16–1.95) 0.002 1.32 (1.01–1.73) 0.049 
BMI/WL Grade 1.77 (1.23–2.55) 0.002 1.50 (1.02–2.19) 0.037 
Table 6e     
Timed up and go test failure Univariate p-value Multivariate p-value 
ECOG-PS 5.84 (3.79–9.00) <0.001 5.84 (3.79–9.00) <0.001 
mGPS 1.56 (1.22–1.98) <0.001 ─ 0.231 
BMI/WL Grade 1.20 (0.89–1.61) 0.232 ─ 0.484 
Table 6f     
Hand grip strength test failure Univariate p-value  Multivariate p-value 
ECOG-PS 1.93 (0.97–3.84) 0.060 ─ 0.213 
mGPS 1.95 (1.29–2.97) 0.002 1.95 (1.29–2.97) 0.002 
BMI/WL Grade 1.05 (0.59–1.89) 0.862 ─ 0.621 
The relationship between ECOG-PS, mGPS, BMI/WL grade and high visceral obesity is shown 
in Table 6b. On multivariate binary logistic regression analysis, BMI/WL grade (OR 0.57, 95%CI 0.38–
0.87, p < 0.01) remained independently associated with a high visceral obesity. 
The relationship between ECOG-PS, mGPS, BMI/WL grade and low skeletal muscle index is 
shown in Table 6c. On multivariate binary logistic regression analysis, ECOG-PS (OR 1.90, 95%CI 
1.51–2.39, p < 0.001) remained independently associated with a low skeletal muscle index. 
The relationship between ECOG-PS, mGPS, BMI/WL grade and low skeletal muscle 
radiodensity is shown in Table 6d. On multivariate binary logistic regression analysis, ECOG-PS (OR 
1.68, 95%CI 1.11–2.55, p < 0.05), mGPS (OR 1.32, 95%CI 1.01–1.73, p < 0.05) and BMI/WL grade (OR 
1.50, 95%CI 1.02–2.19, p < 0.05) remained independently associated with a low skeletal muscle 
radiodensity. 
The relationship between ECOG-PS, mGPS, BMI/WL grade and timed up and go test is shown 
in Table 6e. On multivariate binary logistic regression analysis, ECOG-PS (OR 5.84, 95%CI 3.79–9.00, 
p < 0.001) remained independently associated with timed up and go failure. 
The relationship between ECOG-PS, mGPS, BMI/WL grade and hand grip strength is shown in 
Table 6f. On multivariate binary logistic regression analysis, mGPS (OR 1.95, 95%CI 1.29–2.97, p < 
0.01) remained independently associated with hand grip strength failure. 
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4. Discussion 
Over the last decade or so there has been increasing interest in identifying objective criteria to 
define cancer cachexia. This has proven problematic since cancer cachexia is a syndrome impacting 
on quality of life, body composition, physical function, and survival. In the present study, candidate 
criteria were directly compared in terms of their relationship with measures of body composition and 
physical function. ECOG-PS and mGPS were consistently associated with low skeletal muscle mass 
and function and therefore, together with our previous study [11], both ECOG-PS and mGPS would 
appear to pass the duck test as criteria to define cancer cachexia. 
In the present study, poor performance status was significantly associated with low skeletal 
muscle index, low skeletal muscle radiodensity, and timed up and go test failure but not hand grip 
strength test failure. Furthermore, high mGPS was significantly associated with low skeletal muscle 
radiodensity, timed up and go test failure, and hand grip strength test fail. In contrast, high BMI/WL 
grade was significantly associated with high subcutaneous fat index, high visceral obesity, and low 
skeletal muscle radiodensity. Therefore, BMI/WL grade appears to capture elements of the decline in 
fat mass. The present and previous [11] results clearly need to be repeated to prove the clinical utility 
of the ECOG-PS/mGPS framework. However, if this proves to be the case (and these observations are 
readily repeated) there are a number of important implications for the future diagnosis and treatment 
of cancer cachexia. The present results would suggest that in addition to ECOG-PS, mGPS is useful 
in defining the syndrome of cancer cachexia. Therefore, the ECOG/mGPS framework should be 
considered as part of routine assessment prior to treatment in patients with advanced cancer. 
In the present study it was of interest that low skeletal muscle radiodensity was significantly 
associated with timed up and go test failure (p < 0.05) and hand grip strength test failure (p < 0.05). 
These results would be consistent with the results of a recent study by Williams and co-workers who 
reported that skeletal muscle radiodensity was related to physical function impairments including 
activities of daily living (ADL), climbing stairs, walking, and timed up and go [29]. Furthermore, the 
presence of systemic inflammatory response degrades the quality of the skeletal muscle [30]. If this 
were to be the case then it might be anticipated that downregulation of the systemic inflammatory 
response, compared with placebo, would result in better preservation of muscle density, muscle 
strength, and performance status. This hypothesis is the subject of a number of ongoing randomised 
clinical trials. For example, there is a randomised placebo controlled phase III trial underway of a 
multimodal intervention (exercise, nutrition, anti-inflammatory medication) in patients with 
advanced lung or pancreatic cancer undergoing anti-cancer therapy with palliative intent 
(NCT02330926) [31]. The aim of this trial is to prevent or attenuate loss of weight, muscle, and 
physical function using a multimodal intervention which is anti-inflammatory. The findings from the 
associated phase II trial provide grounds for optimism for the ongoing phase III trial [32]. 
In the present study, three criteria were considered to define cachexia. With reference to ECOG-
PS this has long been considered a cornerstone of assessment by oncologists and palliative physicians. 
With the increasing integration of oncology and palliative care this is likely to remain an important 
part of the assessment of the patient with advanced cancer. It may be that other objective 
measurements of “real life” performance status will more consistently reflect ECOG-PS, such as 
activity trackers (e.g., Fitbit) [33–35]. With reference to the mGPS there has been in recent years 
extensive validation of its use in patients with advanced care, and routine assessment is now 
advocated [36,37]. Of the present criteria considered, it is the only one that is completely objective as 
it relies on two routine, laboratory-derived values. Indeed, it has been termed “laboratory cachexia” 
as its values become increasingly abnormal towards death [38] and the mGPS above has been used 
to define cancer cachexia [39,40]. There are other measures of the systemic inflammatory response 
that have been shown to have prognostic value, such as the neutrophil lymphocyte ratio which can 
be collected as part of the routine differential white cell count. However, such ratios have not been 
well defined and their relationship with the syndrome of cachexia has not been shown [7,41,42]. With 
reference to BMI/WL grade it is not clear whether this has additional value to other nutritional risk 
screening tools such as the Malnutrition Universal Screening Tool (MUST) and the Patient Generated 
Subjective Global Assessment (PG-SGA) that are in routine clinical use [36,40]. Therefore, further 
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comparative studies are required to establish the value of BMI/WL grade as a measure of cachexia in 
patients with advanced cancer. 
The findings of the present study may also help inform regulatory endpoints in the arena of 
trials treating cancer cachexia. To date there has been a lack of concordance in regulatory guidance 
between the EMA and FDA regarding endpoints [43] whilst previously agreed endpoints of skeletal 
muscle mass and function have not been realized in multiple clinical trials of varying agents [44–47]. 
It may be that moderating the systemic inflammatory response in patients with advanced cancer will 
produce more reproducible gains. 
Limitations of the present study include that body composition measures and physical function 
test data were not available in all patients. In the present study the data were analysed according to 
clinically relevant criteria (previously reported to be associated with clinical outcomes such as 
survival) rather than statistical criteria. Specifically, categorical rather than continuous analysis was 
used and since only 10 out of 403 subjects passed the two-minute walk test this was excluded from 
further analysis. Furthermore, the cohort was relatively heterogenous with different cancer types and 
specific stages of disease. However, when further stratification of the results was carried out for both 
lung cancers and gastrointestinal cancers in particular (n ~180 each, supplementary Tables S1 and 
S2), similar results were obtained on univariate and multivariate analysis to that of the combined 
cohort, suggesting that the relationships between ECOG-PS, mGPS, BMI/WL grade and skeletal 
muscle index, skeletal muscle density and physical function were not specific to cancer type. With 
reference to stage of disease, more than 80% of patients had metastatic disease on study entry and 
therefore the heterogeneity of this cohort would have been unlikely to confound the present results. 
Importantly, the present results are likely to represent the type of patient cohort being treated by both 
oncologist and palliative care physicians. Further work is required to define these relationships in 
specific tumour types and at specific stages of disease. Furthermore, objective ongoing measurements 
of physical function such as the use of Fitbit monitors would be of considerable interest. 
5. Conclusions 
In summary, a high ECOG-PS and a high mGPS as outlined in the ECOG-PS/mGPS framework 
were consistently associated with poorer body composition and physical function in patients with 
advanced cancer. The simplicity and clinical utility of this framework mean that it can be readily 
incorporated into the routine assessment of patients with advanced cancer. 
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S1: The relationship between ECOG-PS, mGPS, BMI/WL grade and SMI, SMD and physical function in patients 
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SMI, SMD and physical function in patients with advanced gastrointestinal cancer (n = 180). 
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